$336.85
+1.94
(+0.58%)▲
Stryker Corporation is a medical technology company that develops and manufactures innovative products for orthopedics, spine, and neurotechnology.
Insights on Stryker Corporation
Revenue is up for the last 2 quarters, 4.90B → 5.81B (in $), with an average increase of 15.6% per quarter
Netprofit is up for the last 2 quarters, 692.0M → 1.14B (in $), with an average increase of 39.5% per quarter
In the last 1 year, Boston Scientific Corp. has given 34.4% return, outperforming this stock by 23.5%
In the last 3 years, Boston Scientific Corp. has given 61.5% return, outperforming this stock by 36.1%
0.47%
Downside
Day's Volatility :2.1%
Upside
1.65%
26.16%
Downside
52 Weeks Volatility :31.02%
Upside
6.58%
Period | Stryker Corporation | Sector (Health Care) | S&P500 |
---|---|---|---|
3 Months | 8.83% | 1.9% | 4.1% |
6 Months | 26.35% | 10.7% | 19.4% |
1 Year | 10.88% | 4.6% | 22.6% |
3 Years | 26.25% | 14.2% | 21.3% |
Market Capitalization | 124.7B |
Book Value | $48.92 |
Dividend Share | 3.05 |
Dividend Yield | 0.98% |
Earnings Per Share (EPS) | 8.26 |
PE Ratio | 39.67 |
PEG Ratio | 2.92 |
Wall Street Target Price | 372.04 |
Profit Margin | 15.44% |
Operating Margin TTM | 24.47% |
Return On Assets TTM | 6.87% |
Return On Equity TTM | 17.98% |
Revenue TTM | 20.5B |
Revenue Per Share TTM | 54.0 |
Quarterly Revenue Growth YOY | 11.799999999999999% |
Gross Profit TTM | 11.6B |
EBITDA | 5.2B |
Diluted Eps TTM | 8.26 |
Quarterly Earnings Growth YOY | 1.03 |
EPS Estimate Current Year | 11.85 |
EPS Estimate Next Year | 13.26 |
EPS Estimate Current Quarter | 3.27 |
EPS Estimate Next Quarter | 2.5 |
What analysts predicted
Upside of 10.45%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 13.6B | ↑ 9.3% |
Net Income | 3.6B | ↑ 248.33% |
Net Profit Margin | 26.12% | ↑ 17.92% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 14.9B | ↑ 9.43% |
Net Income | 2.1B | ↓ 41.37% |
Net Profit Margin | 13.99% | ↓ 12.13% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 14.4B | ↓ 3.58% |
Net Income | 1.6B | ↓ 23.24% |
Net Profit Margin | 11.14% | ↓ 2.85% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 17.1B | ↑ 19.21% |
Net Income | 2.0B | ↑ 24.7% |
Net Profit Margin | 11.66% | ↑ 0.52% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 18.4B | ↑ 7.84% |
Net Income | 2.4B | ↑ 18.25% |
Net Profit Margin | 12.78% | ↑ 1.12% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 20.5B | ↑ 11.11% |
Net Income | 3.2B | ↑ 34.22% |
Net Profit Margin | 15.44% | ↑ 2.66% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 4.5B | ↓ 0.31% |
Net Income | 816.0M | ↑ 24.39% |
Net Profit Margin | 18.22% | ↑ 3.62% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 5.2B | ↑ 16.14% |
Net Income | 563.0M | ↓ 31.0% |
Net Profit Margin | 10.82% | ↓ 7.4% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 4.8B | ↓ 8.15% |
Net Income | 592.0M | ↑ 5.15% |
Net Profit Margin | 12.39% | ↑ 1.57% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 5.0B | ↑ 4.56% |
Net Income | 738.0M | ↑ 24.66% |
Net Profit Margin | 14.77% | ↑ 2.38% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 4.9B | ↓ 1.74% |
Net Income | 692.0M | ↓ 6.23% |
Net Profit Margin | 14.1% | ↓ 0.67% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 5.8B | ↑ 18.46% |
Net Income | 1.1B | ↑ 65.17% |
Net Profit Margin | 19.66% | ↑ 5.56% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 27.2B | ↑ 22.75% |
Total Liabilities | 15.5B | ↑ 27.16% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 30.2B | ↑ 10.79% |
Total Liabilities | 17.4B | ↑ 12.01% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 34.3B | ↑ 13.8% |
Total Liabilities | 21.2B | ↑ 22.38% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 34.6B | ↑ 0.88% |
Total Liabilities | 19.8B | ↓ 7.02% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 36.9B | ↑ 6.51% |
Total Liabilities | 20.3B | ↑ 2.6% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 39.9B | ↑ 8.21% |
Total Liabilities | 21.3B | ↑ 5.19% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 36.0B | ↓ 0.14% |
Total Liabilities | 19.5B | ↓ 4.12% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 36.9B | ↑ 2.5% |
Total Liabilities | 20.3B | ↑ 3.83% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 36.8B | ↓ 0.15% |
Total Liabilities | 19.9B | ↓ 1.64% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 37.4B | ↑ 1.57% |
Total Liabilities | 20.0B | ↑ 0.57% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 38.0B | ↑ 1.69% |
Total Liabilities | 20.1B | ↑ 0.44% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 39.9B | ↑ 4.92% |
Total Liabilities | 21.3B | ↑ 5.87% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 2.6B | ↑ 67.42% |
Investing Cash Flow | -2.9B | ↑ 77.12% |
Financing Cash Flow | 1.3B | ↓ 267.38% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 2.2B | ↓ 16.05% |
Investing Cash Flow | -1.5B | ↓ 49.07% |
Financing Cash Flow | 3.0M | ↓ 99.77% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 3.3B | ↑ 49.57% |
Investing Cash Flow | -4.7B | ↑ 223.09% |
Financing Cash Flow | -11.0M | ↓ 466.67% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 3.3B | ↓ 0.43% |
Investing Cash Flow | -859.0M | ↓ 81.73% |
Financing Cash Flow | -2.4B | ↑ 21400.0% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 2.6B | ↓ 19.58% |
Investing Cash Flow | -2.9B | ↑ 240.4% |
Financing Cash Flow | -749.0M | ↓ 68.33% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 889.0M | ↑ 68.05% |
Investing Cash Flow | -2.8B | ↑ 1717.11% |
Financing Cash Flow | -543.0M | ↓ 27.89% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 1.0B | ↑ 12.82% |
Investing Cash Flow | -2.9B | ↑ 5.87% |
Financing Cash Flow | -446.0M | ↓ 17.86% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 445.0M | ↓ 55.63% |
Investing Cash Flow | -132.0M | ↓ 95.49% |
Financing Cash Flow | -481.0M | ↑ 7.85% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 688.0M | ↑ 54.61% |
Investing Cash Flow | -533.0M | ↑ 303.79% |
Financing Cash Flow | -405.0M | ↓ 15.8% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 1.1B | ↑ 52.62% |
Investing Cash Flow | -810.0M | ↑ 51.97% |
Financing Cash Flow | -422.0M | ↑ 4.2% |
Sell
Neutral
Buy
Stryker Corporation is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Stryker Corporation | -4.59% | 26.35% | 10.88% | 26.25% | 80.99% |
Boston Scientific Corp. | 2.53% | 35.38% | 34.38% | 63.21% | 94.67% |
Edwards Lifesciences Corp. | -5.81% | 24.49% | -1.17% | -8.62% | 48.12% |
Abbott Laboratories | -2.2% | 13.48% | -2.55% | -12.23% | 40.18% |
Medtronic Plc | -2.34% | 12.97% | -9.37% | -37.53% | -5.08% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Stryker Corporation | 39.67 | 39.67 | 2.92 | 11.85 | 0.18 | 0.07 | 0.01 | 48.92 |
Boston Scientific Corp. | 63.57 | 63.57 | 1.8 | 2.25 | 0.09 | 0.04 | NA | 13.16 |
Edwards Lifesciences Corp. | 38.15 | 38.15 | 5.19 | 2.75 | 0.22 | 0.12 | NA | 11.06 |
Abbott Laboratories | 33.36 | 33.36 | 5.99 | 4.61 | 0.15 | 0.06 | 0.02 | 22.26 |
Medtronic Plc | 25.58 | 25.58 | 1.52 | 5.2 | 0.08 | 0.04 | 0.03 | 38.95 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Stryker Corporation | Buy | $124.7B | 80.99% | 39.67 | 15.44% |
Boston Scientific Corp. | Buy | $100.0B | 94.67% | 63.57 | 11.18% |
Edwards Lifesciences Corp. | Buy | $52.8B | 48.12% | 38.15 | 23.36% |
Abbott Laboratories | Buy | $185.8B | 40.18% | 33.36 | 13.96% |
Medtronic Plc | Buy | $107.0B | -5.08% | 25.58 | 13.0% |
Vanguard Group Inc
BlackRock Inc
Greenleaf Trust
State Street Corporation
T. Rowe Price Associates, Inc.
Wellington Management Company LLP
In the quarter ending March,2024. Stryker Corporation has declared dividend of $0.8
Read MoreStryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan.
Organization | Stryker Corporation |
Employees | 52000 |
CEO | Mr. Kevin A. Lobo |
Industry | Health Technology |
Molina Healthcare, Inc.
$336.85
+0.58%
Icici Bank Ltd.
$336.85
+0.58%
Globalfoundries Inc.
$336.85
+0.58%
Lpl Financial Holdings Inc.
$336.85
+0.58%
Ares Capital Corporation
$336.85
+0.58%
Cognizant Technology Solutions Corp.
$336.85
+0.58%
Illinois Tool Works Inc.
$336.85
+0.58%
Schwab Us Large-cap Growth Etf
$336.85
+0.58%
Union Pacific Corporation
$336.85
+0.58%